Protalix BioTherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1996
Revenue	65.49	47.64	38.35	62.9	54.69	34.24	21.08	9.2	4.36	3.52	Upgrade
Revenue Growth (YoY)	37.48%	24.22%	-39.03%	15.00%	59.73%	62.44%	129.13%	110.79%	23.87%	-	Upgrade
Cost of Revenue	22.98	19.59	16.35	10.87	10.9	9.3	15.23	8.4	0.73	0.63	Upgrade
Gross Profit	42.51	28.05	22	52.03	43.8	24.94	5.85	0.8	3.63	2.89	Upgrade
Selling, General & Admin	14.96	11.71	12.73	11.15	9.9	10.92	11.53	9.36	7.28	9.23	Upgrade
Research & Development	17.09	29.35	29.73	38.17	44.62	33.33	28.83	24.61	20.03	22.22	Upgrade
Operating Expenses	32.05	41.06	42.46	49.32	54.52	44.25	40.36	33.96	27.3	31.45	Upgrade
Operating Income	10.46	-13.01	-20.46	2.71	-10.72	-19.31	-34.52	-33.16	-23.67	-28.56	Upgrade
Interest Expense / Income	1.89	1.38	7.12	9.23	7.56	7.15	48.92	4.19	3.74	4.94	Upgrade
Other Expense / Income	-	-	-	-	-	-	-	-7.99	-85.44	-3.55	Upgrade
Pretax Income	8.57	-14.4	-27.58	-6.52	-18.28	-26.46	-83.44	-29.37	58.04	-29.94	Upgrade
Income Tax	0.25	0.53	0	0	0	0	0	0	0	0	Upgrade
Net Income	8.31	-14.93	-27.58	-6.52	-18.28	-26.46	-83.44	-29.37	58.04	-29.94	Upgrade
Shares Outstanding (Basic)	68	48	44	29	15	15	13	10	9	9	Upgrade
Shares Outstanding (Diluted)	82	48	44	29	15	15	13	10	9	9	Upgrade
Shares Change	70.04%	9.81%	51.43%	96.44%	0.85%	12.24%	29.29%	6.81%	2.19%	0.57%	Upgrade
EPS (Basic)	0.12	-0.31	-0.62	-0.22	-1.23	-1.80	-6.37	-2.90	6.10	-3.20	Upgrade
EPS (Diluted)	0.09	-0.31	-0.62	-0.22	-1.23	-1.80	-6.37	-2.90	6.10	-3.20	Upgrade
Free Cash Flow	-2.47	-25.63	-11.69	-26.76	-19.99	-8.43	-10.96	-32.93	-24.75	-30.06	Upgrade
Free Cash Flow Per Share	-0.04	-0.53	-0.27	-0.92	-1.35	-0.57	-0.84	-3.25	-2.61	-3.23	Upgrade
Gross Margin	64.91%	58.87%	57.37%	82.71%	80.08%	72.83%	27.74%	8.71%	83.27%	82.12%	Upgrade
Operating Margin	15.97%	-27.32%	-53.36%	4.31%	-19.59%	-56.39%	-163.76%	-360.51%	-542.39%	-810.64%	Upgrade
Profit Margin	12.69%	-31.33%	-71.92%	-10.37%	-33.42%	-77.27%	-395.86%	-319.22%	1329.90%	-849.93%	Upgrade
Free Cash Flow Margin	-3.77%	-53.80%	-30.49%	-42.55%	-36.54%	-24.61%	-52.01%	-357.94%	-567.03%	-853.11%	Upgrade
Effective Tax Rate	2.97%	-	-	-	-	-	-	-	-	-	Upgrade
EBITDA	11.65	-11.93	-19.34	4.01	-9.1	-17.64	-32.6	-23.19	64.14	-21.87	Upgrade
EBITDA Margin	17.79%	-25.04%	-50.44%	6.38%	-16.64%	-51.51%	-154.65%	-252.09%	1469.80%	-620.72%	Upgrade
Depreciation & Amortization	1.19	1.09	1.12	1.3	1.62	1.67	1.92	1.98	2.37	3.14	Upgrade
EBIT	10.46	-13.01	-20.46	2.71	-10.72	-19.31	-34.52	-25.17	61.77	-25.01	Upgrade
EBIT Margin	15.97%	-27.32%	-53.36%	4.31%	-19.59%	-56.39%	-163.76%	-273.65%	1415.49%	-709.85%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).